UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals ONXX. In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in cash. Our last rating on the stock was Hold. Our FY13 estimates for ONXX were EPS of $(2.92) and $626M of revenues.” Onyx Pharmaceuticals closed on Thursday at $124.70.